Vorasidenib
Orphan DrugFDA Approved
Contents
Description
Vorasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-1 and 2 (IDH1/2) enzymes. It is indicated for adult patients with IDH1- or IDH2-mutant low-grade glioma.
Indications & Therapeutic Use
Low-grade glioma
Linked Diseases:
oligodendroglioma
C71D009837
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Buy / Source Vorasidenib — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Vorasidenib products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vorasidenib
| Generic Name | Vorasidenib |
| Brands | 1 brand available |
| Active Ingredient | Vorasidenib |
| Drug Class | Low-grade glioma |
| Manufacturer | Servier Pharmaceuticals |
| Dosage Forms | Tablet |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT04164901 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes